Influenza A virus subtype H10N8
Influenza A virus subtype H10N8 is a subtype of the Influenza A virus that had been detected in birds in the past. This subtype has been identified as a potential future pandemic threat.
History[edit]
The first human case of H10N8 was reported in China in December 2013. The patient was a 73-year-old woman from Nanchang City. She had visited a live poultry market a few days before the onset of illness. She was admitted to hospital with severe pneumonia and died of multi-organ failure on 6 December 2013.
Virology[edit]
Influenza A virus subtype H10N8 is a subtype of viruses that causes influenza (flu). Influenza A subtypes are classified based on two proteins on the surface of the virus, hemagglutinin (H) and neuraminidase (N). In the case of H10N8, the virus has an H10 hemagglutinin and an N8 neuraminidase.
Transmission[edit]
The exact mode of transmission of H10N8 is not known. However, it is believed that the virus is transmitted from birds to humans. The virus has been detected in live poultry markets, suggesting that these markets may be a source of human infections.
Symptoms[edit]
The symptoms of H10N8 infection are similar to those of other types of influenza. They include fever, cough, sore throat, muscle aches, and fatigue. In severe cases, the infection can lead to pneumonia and multi-organ failure.
Prevention and Treatment[edit]
There is currently no vaccine available for H10N8. Prevention strategies include avoiding exposure to infected birds and practicing good hygiene. Antiviral drugs can be used to treat the infection.
See Also[edit]
| Influenza | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian